Cyclacel Pharmaceuticals, Inc.
CYCCNASDAQHealthcare
$6.37
$-0.41(-5.98%)
Market Cap$10608329
P/E Ratio—
52W High$597.59973
52W Low$3.0801
Cyclacel Pharmaceuticals, Inc. (CYCC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CYCC · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 13, 2025EPS Actual
-$0.00
Est. -$72.00 · +100.0%
Revenue
$0.00B
Est. $0.00B · +224.0%
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 13, 2025
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
CYCC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 13, 2025 | -$72.00 | -$0.00 | +100.0% | $0.00B | $0.00B | +224.0% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$72.00 | -$0.98 | +98.6% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$69.60 | -$6.25 | +91.0% | — | $0.00B | — |
| ▼ Q2 FY2025 | Apr 2, 2025 | -$4.64 | -$5.28 | -13.8% | $-0.00B | $0.00B | -450.0% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.54 | -$0.18 | +66.7% | $0.00B | $0.00B | +0.0% |
| ▲ Q3 FY2024 | Aug 14, 2024 | -$0.83 | -$0.72 | +13.3% | $0.00B | $0.00B | -86.7% |
| ▲ Q2 FY2024 | May 14, 2024 | -$4.93 | -$2.27 | +54.0% | $0.00B | — | — |
| ▲ Q1 FY2024 | Mar 19, 2024 | -$6.35 | -$6.23 | +1.9% | $0.00B | — | — |
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.00
EPS Est.
-$72.00
EPS Surpr.
+100.0%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.98
EPS Est.
-$72.00
EPS Surpr.
+98.6%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$6.25
EPS Est.
-$69.60
EPS Surpr.
+91.0%
Revenue
—
Q2 FY2025
Apr 2, 2025Miss
EPS Actual
-$5.28
EPS Est.
-$4.64
EPS Surpr.
-13.8%
Revenue
$-0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.18
EPS Est.
-$0.54
EPS Surpr.
+66.7%
Revenue
$0.00B
Q3 FY2024
Aug 14, 2024Beat
EPS Actual
-$0.72
EPS Est.
-$0.83
EPS Surpr.
+13.3%
Revenue
$0.00B
Q2 FY2024
May 14, 2024Beat
EPS Actual
-$2.27
EPS Est.
-$4.93
EPS Surpr.
+54.0%
Revenue
$0.00B
Q1 FY2024
Mar 19, 2024Beat
EPS Actual
-$6.23
EPS Est.
-$6.35
EPS Surpr.
+1.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-72.00 | $-72.00 | $-72.00 | 1 |
| Q3 FY2025 | $-72.00 | $-72.00 | $-72.00 | 1 |
| Q2 FY2025 | $-72.00 | $-72.00 | $-72.00 | 1 |
| Q1 FY2025 | $-69.60 | $-69.60 | $-69.60 | 1 |
| Q4 FY2024 | $-69.60 | $-69.60 | $-69.60 | 1 |
| Q3 FY2024 | $-129.60 | $-129.60 | $-129.60 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 13, 2025 | +100.0% | $5.16 | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | +98.6% | $9.28 | $8.90 | -4.09% |
| ▲ Q2 FY2025 | May 15, 2025 | +91.0% | $34.80 | $33.00 | -5.17% |
| ▼ Q2 FY2025 | Apr 2, 2025 | -13.8% | $64.56 | $58.85 | -8.84% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +66.7% | $107.76 | $98.40 | -8.69% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +13.3% | $329.69 | $348.00 | +5.55% |
| ▲ Q2 FY2024 | May 14, 2024 | +54.0% | $609.60 | $681.60 | +11.81% |
| ▲ Q1 FY2024 | Mar 19, 2024 | +1.9% | $602.40 | $564.00 | -6.37% |
Q4 FY2025—
Report Date
Nov 13, 2025
EPS Beat/Miss
+100.0%
Price Before
$5.16
Price After
—
Q3 FY2025-4.09%
Report Date
Aug 13, 2025
EPS Beat/Miss
+98.6%
Price Before
$9.28
Price After
$8.90
Q2 FY2025-5.17%
Report Date
May 15, 2025
EPS Beat/Miss
+91.0%
Price Before
$34.80
Price After
$33.00
Q2 FY2025-8.84%
Report Date
Apr 2, 2025
EPS Beat/Miss
-13.8%
Price Before
$64.56
Price After
$58.85
Q4 FY2024-8.69%
Report Date
Nov 12, 2024
EPS Beat/Miss
+66.7%
Price Before
$107.76
Price After
$98.40
Q3 FY2024+5.55%
Report Date
Aug 14, 2024
EPS Beat/Miss
+13.3%
Price Before
$329.69
Price After
$348.00
Q2 FY2024+11.81%
Report Date
May 14, 2024
EPS Beat/Miss
+54.0%
Price Before
$609.60
Price After
$681.60
Q1 FY2024-6.37%
Report Date
Mar 19, 2024
EPS Beat/Miss
+1.9%
Price Before
$602.40
Price After
$564.00
Avg Beat Reaction-1.16%
Avg Miss Reaction-8.84%
Beat Rate7 / 8 quarters
Largest Move+11.81% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CYCC ends December
Cyclacel Pharmaceuticals, Inc. (CYCC) most recently reported earnings on November 13, 2025 for Q4 FY2025, posting EPS of $-0.00 — beating the analyst consensus of $-72.00 by +100.0%. CYCC has beaten EPS estimates for 3 consecutive quarters. The next CYCC earnings date is expected around September 1, 2026.
Each quarter, investors track CYCC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CYCC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CYCC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CYCC earnings · 5 questionsCyclacel Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. CYCC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CYCC historically reports after market close (AMC).
CYCC earnings datewhen is CYCC earningsCYCC next earnings datewhen does CYCC report earningsCYCC earnings calendar
▸ Source: FMP · Cyclacel Pharmaceuticals, Inc. SEC filings · US GAAP · Cyclacel Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026